Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Best overall response assessment by irRC simulating RECIST1.0 and irRC simulatin RECIST1.1 in 71 patients who had at least one follow-up CT

From: Optimizing immune-related tumor response assessment: does reducing the number of lesions impact response assessment in melanoma patients treated with ipilimumab?

  Assessment by irRC simulating RECIST1.0  
Assessment by irRC simulating RECIST1.1 irCR irPR irSD irPD  
irCR 1 1 0 0 1
irPR 0 8 1 0 10
irSD 0 0 52 1 53
irPD 0 0 1 6 7
  1 9 54 7 71
  1. κw = 0.908 (95% CI: 0.82-0.99).